Update on marine omega-3 fatty acids: Management of dyslipidemia and current omega-3 treatment options

Atherosclerosis

Volumn 230, Issue 2, 2013, Pages 381-389

  Weintraub, Howard ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Docosahexaenoic acid; Dyslipidemia; Eicosapentaenoic acid; Fish oil; Omega 3 fatty acid

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; DOCOSAHEXAENOIC ACID; EPANOVA; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; OLIVE OIL; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; OMEGA 3 FREE FATTY ACID; SIMVASTATIN; UNCLASSIFIED DRUG; VEGETABLE OIL;

ACUTE HEART INFARCTION; ARTERIAL WALL THICKNESS; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CONSTIPATION; CREATININE BLOOD LEVEL; DEPRESSED BLOOD PRESSURE; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; ERUCTATION; EXERCISE; FAMILIAL HYPERCHOLESTEROLEMIA; FISH; FLUSHING; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; KRILL; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); TASTE DISORDER; THROMBOSIS;

DOCOSAHEXAENOIC ACID; DYSLIPIDEMIA; EICOSAPENTAENOIC ACID; FISH OIL; OMEGA 3 FATTY ACID;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIET; DOCOSAHEXAENOIC ACIDS; DYSLIPIDEMIAS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FISH PRODUCTS; FISHES; HUMANS; HYPERTRIGLYCERIDEMIA; PLANT OILS; RISK; TREATMENT OUTCOME;

EID: 84884546418     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.07.041     Document Type: Review

References (78)

1. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAm Med Assoc 1984, 251(3):351-364.
2. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAm Med Assoc 1984, 251(3):365-374.
3. Rossouw J.E., Lewis B., Rifkind B.M. The value of lowering cholesterol after myocardial infarction. NEngl J Med 1990, 323(16):1112-1119.
4. Pekkanen J., Linn S., Heiss G., Suchindran C.M., Leon A., Rifkind B.M., et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. NEngl J Med 1990, 322(24):1700-1707.
5. Cohen J.D., Cziraky M.J., Cai Q., Wallace A., Wasser T., Crouse J.R., et al. 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006. Am J Cardiol 2010, 106(7):969-975.
6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143-3421.
7. Fruchart J.C., Sacks F.M., Hermans M.P., Assmann G., Brown W.V., Ceska R., et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes Vasc Dis Res 2008, 5(4):319-335.
8. Miller M., Stone N.J., Ballantyne C., Bittner V., Criqui M.H., Ginsberg H.N., et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123(20):2292-2333.
9. Ford E.S., Li C., Zhao G., Pearson W.S., Mokdad A.H. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009, 169(6):572-578.
10. Weitz D., Weintraub H., Fisher E., Schwartzbard A.Z. Fish oil for the treatment of cardiovascular disease. Cardiol Rev 2010, 18(5):258-263.
11. Wei M.Y., Jacobson T.A. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep 2011, 13(6):474-483.
12. Jacobson T.A., Glickstein S.B., Rowe J.D., Soni P.N. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. JClin Lipidol 2012, 6(1):5-18.
13. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110(2):227-239.
14. Zetia [package insert] 2013, Merck & Co., Inc., Whitehouse Station, NJ.
15. Kris-Etherton P.M., Harris W.S., Appel L.J. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 2003, 23(2):151-152.
16. Bang H.O., Dyerberg J. Plasma lipids and lipoproteins in Greenlandic west coast Eskimos. Acta Med Scand 1972, 192(1-2):85-94.
17. Whelton S.P., He J., Whelton P.K., Muntner P. Meta-analysis of observational studies on fish intake and coronary heart disease. Am J Cardiol 2004, 93(9):1119-1123.
18. He K., Song Y., Daviglus M.L., Liu K., Van H.L., Dyer A.R., et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 2004, 109(22):2705-2711.
19. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. NEngl J Med 1999, 341(6):410-418.
20. Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002, 162(22):2597-2604.
21. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366(9500):1849-1861.
22. Ginsberg H.N., Elam M.B., Lovato L.C., Crouse J.R., Leiter L.A., Linz P., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. NEngl J Med 2010, 362(17):1563-1574.
23. Lee M., Saver J.L., Towfighi A., Chow J., Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011, 217(2):492-498.
24. Boden W.E., Probstfield J.L., Anderson T., Chaitman B.R., Desvignes-Nickens P., Koprowicz K., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. NEngl J Med 2011, 365(24):2255-2267.
25. Capuzzi D.M., Guyton J.R., Morgan J.M., Goldberg A.C., Kreisberg R.A., Brusco O.A., et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998, 82(12A):74U-81U.
26. Armitage J. HPS2-THRIVE: randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease [oral presentation] Presented at the Annual Scientific Session of the American College of Cardiology 2013, CA, San Francisco, March 9-11.
27. Knapp H.H., Schrott H., Ma P., Knopp R., Chin B., Gaziano J.M., et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001, 110(5):352-360.
28. Ast M., Frishman W.H. Bile acid sequestrants. JClin Pharmacol 1990, 30(2):99-106.
29. Welchol [package insert] 2012, Daiichi Sankyo Inc., Parsippany, NJ.
30. Kastelein J.J., Akdim F., Stroes E.S., Zwinderman A.H., Bots M.L., Stalenhoef A.F., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. NEngl J Med 2008, 358(14):1431-1443.
31. IMPROVE-IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin (P04103 AM5) NCT00202878. ClinicalTrials.gov. Available from: , [accessed 06.05.13]. http://clinicaltrials.gov/show/NCT00202878.
32. Nestel P., Shige H., Pomeroy S., Cehun M., Abbey M., Raederstorff D. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr 2002, 76(2):326-330.
33. Ando M., Sanaka T., Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents invivo peroxidation of LDL in dialysis patients. JAm Soc Nephrol 1999, 10(10):2177-2184.
34. Kurabayashi T., Okada M., Tanaka K. Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women. The Niigata Epadel Study Group. Obstet Gynecol 2000, 96(4):521-528.
35. Satoh N., Shimatsu A., Kotani K., Sakane N., Yamada K., Suganami T., et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 2007, 30(1):144-146.
36. Tatsuno I., Saito Y., Kudou K., Ootake J. Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study. JClin Lipidol 2013, 7(3):199-207.
37. Lovaza [package insert] 2012, GlaxoSmithKline, Research Triangle Park, NC.
38. Epadel [package insert] 2007, Mochida Pharmaceutical Co., Ltd, Tokyo, Japan.
39. Harris W.S., Ginsberg H.N., Arunakul N., Shachter N.S., Windsor S.L., Adams M., et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. JCardiovasc Risk 1997, 4(5-6):385-391.
40. Pownall H.J., Brauchi D., Kilinc C., Osmundsen K., Pao Q., Payton-Ross C., et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 1999, 143(2):285-297.
41. Davidson M.H., Stein E.A., Bays H.E., Maki K.C., Doyle R.T., Shalwitz R.A., et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007, 29(7):1354-1367.
42. Bays H.E., McKenney J., Maki K.C., Doyle R.T., Carter R.N., Stein E. Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc 2010, 85(2):122-128.
43. Tricor [package insert] 2010, Abbott Laboratories, North Chicago, IL.
44. Niaspan [package insert] 2010, Abbott Laboratories, North Chicago, IL.
45. Bays H.E., Ballantyne C.M., Kastelein J.J., Isaacsohn J.L., Braeckman R.A., Soni P.N. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011, 108(5):682-690.
46. Ballantyne C.M., Bays H.E., Kastelein J.J., Stein E., Isaacsohn J.L., Braeckman R.A., et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012, 110(7):984-992.
47. Davidson M.H., Kling D., Maki K.C. Novel developments in omega-3 fatty acid-based strategies. Curr Opin Lipidol 2011, 22(6):437-444.
48. Davidson M.H., Johnson J., Rooney M.W., Kyle M.L., Kling D.F. Anovel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova compared to Lovaza in a pharmacokinetic single-dose evaluation) study. JClin Lipidol 2012, 6(6):573-584.
49. Omthera Pharmaceuticals announces positive top-line results from phase 3 EVOLVE study. Omthera Pharmaceuticals. Available from: , [accessed 06.05.13]. http://www.omthera.com/pdf/EVOLVE_Data_Final.pdf.
50. Kastelein J.J., Maki K.C., Susekov A., Ezhov M., Nordestgaard B.G., Kling D., et al. Dose response of a novel free-fatty acid formulation of omega-3 for the management of dyslipidemia in patients with severe hypertriglyceridemia - EpanoVa fOr Lowering Very High TriglycErides (the EVOLVE trial) [abstract 16374]. Circulation 2012, 126:A16374.
51. Efficacy and safety of add-on Epanova® to statin in subjects with persistent hypertriglyceridemia and high risk for cardiovascular disease (ESPRIT). NCT01408303. ClinicalTrials.gov. Available from: , [accessed 06.05.13]. http://www.clinicaltrials.gov/ct2/show/NCT01408303?term=nct01408303%26rank=1.
52. Maki K.C., Orloff D., Nicholls S., Dunbar R., Roth E., Curcio D.L., et al. Ahighly bioavailable omega-3 free-fatty acid reduces non-high density lipoprotein cholesterol in high-risk patients treated with a statin and residual hypertriglycerigemia (ESPRIT trial) [abstract]. JAm Coll Cardiol 2013, 61(10 Suppl.):E1468.
53. Bunea R., El Farrah K., Deutsch L. Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia. Altern Med Rev 2004, 9(4):420-428.
54. TRIal For Efficacy of Capre on hyperTriglyceridemiA (TRIFECTA). NCT01455844. Available from: , [accessed 06.05.13]. http://clinicaltrials.gov/ct2/show/NCT01455844?term=%2528TRIFECTA%2529.%26rank=1.
55. Study to investigate the effects of krill oil on fasting serum triglycerides. NCT01415388. ClinicalTrials.gov. Available from: , [accessed 06.05.13]. http://www.clinicaltrials.gov/ct2/show/NCT01415388?term=NCT01415388%26rank=1.
56. Sijtsma L., de Swaaf M.E. Biotechnological production and applications of the omega-3 polyunsaturated fatty acid docosahexaenoic acid. Appl Microbiol Biotechnol 2004, 64(2):146-153.
57. Bernstein A.M., Ding E.L., Willett W.C., Rimm E.B. Ameta-analysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease. JNutr 2012, 142(1):99-104.
58. Tur J.A., Bibiloni M.M., Sureda A., Pons A. Dietary sources of omega 3 fatty acids: public health risks and benefits. Br J Nutr 2012, 107(Suppl.2):S23-S52.
59. Pan A., Chen M., Chowdhury R., Wu J.H., Sun Q., Campos H., et al. alpha-Linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr 2012, 96(6):1262-1273.
60. Ramsden C.E., Zamora D., Leelarthaepin B., Majchrzak-Hong S.F., Faurot K.R., Suchindran C.M., et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. Br Med J 2013, 346:e8707.
61. Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., Ishikawa Y., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369(9567):1090-1098.
62. Saito Y., Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Ishikawa Y., et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from theJapan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008, 200(1):135-140.
63. GISSI Prevenzione Investigators Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354(9177):447-455.
64. GISSI-HF Investigators Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372(9645):1223-1230.
65. Kromhout D., Giltay E.J., Geleijnse J.M. n-3 fatty acids and cardiovascular events after myocardial infarction. NEngl J Med 2010, 363(21):2015-2026.
66. Rauch B., Schiele R., Schneider S., Diller F., Victor N., Gohlke H., et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010, 122(21):2152-2159.
67. ORIGIN Trial Investigators n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. NEngl J Med 2012, 367(4):309-318.
68. Mozaffarian D., Marchioli R., Macchia A., Silletta M.G., Ferrazzi P., Gardner T.J., et al. Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative AtrialFibrillation (OPERA) randomized trial. JAm Med Assoc 2012, 308(19):2001-2011.
69. Larsson S.C., Orsini N., Wolk A. Long-chain omega-3 polyunsaturated fatty acids and risk of stroke: a meta-analysis. Eur J Epidemiol 2012, 27(12):895-901.
70. A study of AMR101 to evaluate its ability to reduce cardiovascular eventsinhigh risk patients with hypertriglyceridemia and on statin (REDUCE-IT). Available from: , [accessed 06.05.13]. http://clinicaltrials.gov/show/NCT01492361.
71. Wu J.H., Micha R., Imamura F., Pan A., Biggs M.L., Ajaz O., et al. Omega-3 fatty acids and incident type 2 diabetes: a systematic review and meta-analysis. Br J Nutr 2012, 107(Suppl.2):S214-S227.
72. Collins N., Tighe A.P., Brunton S.A., Kris-Etherton P.M. Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective. JAm Coll Nutr 2008, 27(6):659-666.
73. Food and Drug Administration. Dietary supplements. Food and Drug Administration; Available from: , [accessed 06.05.13]. http://www.fda.gov/Food/DietarySupplements/UsingDietarySupplements/ucm109760.htm.
74. Fish oil and omega-3 fatty acid supplements (EPA and DHA from fish, algae, and krill). Consumer Lab; Available from: , [accessed 06.05.13]. http://www.consumerlab.com/reviews/fish_oil_supplements_review/omega3.
75. Vascepa [package insert] 2012, Amarin Pharma Inc., Bedminster, NJ.
76. ® and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy. Future Cardiol 2013, 9(2):177-186.
77. Zargar A., Ito M.K. Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database. Metab Syndr Relat Disord 2011, 9(4):255-271.
78. Krill oil. Monograph. Altern Med Rev 2010, 15(1):84-86.